21:49 , Jan 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver disease; non-alcoholic steatohepatitis (NASH) Mouse and monkey studies suggest promoting CYLD expression could help treat non-alcoholic fatty liver disease (NAFLD) and NASH. In mouse models of diet-induced NAFLD and NASH, CYLD overexpression in hepatocytes...
01:00 , Jan 3, 2018 |  BC Extra  |  Preclinical News

CYLD expression could slow progression of NASH

In a paper published in Nature Medicine, researchers at Wuhan University and Weill Cornell Medicine found that increasing expression of the deubiquitinating enzyme cylindromatosis turban tumor syndrome (CYLD) reversed progression of non-alcoholic steatohepatitis (NASH) in...
07:00 , Jun 4, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer ...